Global: Other adverse effects than tardive dyskinesia Self‐report by participants · patients with antipsychotic‐induced tardive dyskinesia
Pyridoxal 5 phosphate (vitamin B6) showed no clear difference in global: Other adverse effects than tardive dyskinesia Self‐report by… compared with placebo (low certainty).
1 finding from 1 review
Global: Discontinuation of Vitamin B6 · patients with antipsychotic‐induced tardive dyskinesia
Pyridoxal 5 phosphate (vitamin B6) showed no clear difference in global: Discontinuation of Vitamin B6 compared with placebo (low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
Pyridoxal 5 phosphate (vitamin B6) showed no clear difference in tardive dyskinesia: Deterioration in tardive dyskinesia symptoms ESRS1 compared with placebo (low certainty).
1 finding from 1 review
General mental state: Positive psychiatric symptom score PANSS5. Scale from: 7 to 49. · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
General mental state: Negative psychiatric symptoms PANSS5. Scale from: 7 to 49. · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Siblings' quality of life ‐ by 12 months (reversed FAD, high = good) Reversed FAD. Scale from: 4 to 28. · Siblings of people with severe mental illness
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Low
Siblings' coping (in terms of burden) ‐ by 12 months (FBIS, high = poor) · Siblings of people with severe mental illness
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Low
Leaving the study early · Siblings of people with severe mental illness
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Low
Mental state · Siblings of people with severe mental illness
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Low
Service users' number of re‐hospitalisation to a psychiatric inpatient unit over six months ‐ by 12 months · Siblings of people with severe mental illness
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Low
Health service outcomes: 2. Hospital bed‐days by 12 months · Siblings of people with severe mental illness
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Low
Social functioning · Siblings of people with severe mental illness
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Low
Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia
YOGA probably leads to lower mental state: Overall ‐ not improved PANSS compared with STANDARD CARE (moderate certainty).
1 finding from 1 review
Social functioning · patients with schizophrenia
YOGA showed no clear difference in social functioning: Overall ‐ not improved SOFS compared with STANDARD CARE (moderate certainty).
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · patients with schizophrenia
1 finding from 1 review
Physical quality of life · patients with schizophrenia
1 finding from 1 review
Adverse events: any · patients with schizophrenia
1 finding from 1 review
Economic outcomes: Cost of care · patients with schizophrenia
1 finding from 1 review
Leaving the study early Leaving the study early: participants lost to · patients with schizophrenia
YOGA showed no clear difference in leaving the study early Leaving the study early: participants lost to compared with STANDARD CARE (moderate certainty).
1 finding from 1 review
Clinically significant response on global state · patients with schizophrenia
It is very uncertain whether ZUCLOPENTHIXOL DIHYDROCHLORIDE changes clinically significant response on global state ‐ as defined by each… compared with PLACEBO (very low certainty).
1 finding from 1 review